EP1274862A4 - Control of a gene induced by oxidized lipids in human artery wall cells - Google Patents

Control of a gene induced by oxidized lipids in human artery wall cells

Info

Publication number
EP1274862A4
EP1274862A4 EP01923022A EP01923022A EP1274862A4 EP 1274862 A4 EP1274862 A4 EP 1274862A4 EP 01923022 A EP01923022 A EP 01923022A EP 01923022 A EP01923022 A EP 01923022A EP 1274862 A4 EP1274862 A4 EP 1274862A4
Authority
EP
European Patent Office
Prior art keywords
oxidised
phospholipid
mammal
atherosclerosis
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01923022A
Other languages
German (de)
French (fr)
Other versions
EP1274862A1 (en
Inventor
Alan M Fogelman
Mohamad Navab
Susan Hama
Srinivasa T Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/541,468 external-priority patent/US6596544B1/en
Application filed by University of California filed Critical University of California
Publication of EP1274862A1 publication Critical patent/EP1274862A1/en
Publication of EP1274862A4 publication Critical patent/EP1274862A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)

Abstract

A kit for evaluating the risk of atherosclerosis in a mammal, said kit comprising a container containing one or more oxidised or non-oxidized phospholipids, and instructional materials describing the following assay for evaluating the risk of atherosclerosis in a mammal: (A) contacting a high density lipoprotein (HDL) comprised in a biological sample from said mammal with an oxidised phospholipid; and measuring a change in the amount of oxidised or non-oxidised phospholipid wherein the absence of change in the amount of oxidised phospholipid indicates the mammal is at risk of atherosclerosis or (B) contacting a high density lipoprotein (HDL) comprised in a biological sample from said mammal with a phospholipid; subjecting the phospholipid to oxidising conditions; and measuring a change in the amount of oxidised or non-oxidised phospholipid wherein a change in the amount of oxidised or non-oxidised phospholipid indicates the mammal is at risk for atherosclerosis
EP01923022A 2000-03-31 2001-03-29 Control of a gene induced by oxidized lipids in human artery wall cells Withdrawn EP1274862A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US53956900A 2000-03-31 2000-03-31
US541468 2000-03-31
US539569 2000-03-31
US09/541,468 US6596544B1 (en) 2000-03-31 2000-03-31 Functional assay of high-density lipoprotein
PCT/US2001/010590 WO2001075168A1 (en) 2000-03-31 2001-03-29 Control of a gene induced by oxidized lipids in human artery wall cells

Publications (2)

Publication Number Publication Date
EP1274862A1 EP1274862A1 (en) 2003-01-15
EP1274862A4 true EP1274862A4 (en) 2005-06-22

Family

ID=27066136

Family Applications (3)

Application Number Title Priority Date Filing Date
EP01923023A Expired - Lifetime EP1272666B1 (en) 2000-03-31 2001-03-29 A functional assay of high-density lipoprotein
EP01923022A Withdrawn EP1274862A4 (en) 2000-03-31 2001-03-29 Control of a gene induced by oxidized lipids in human artery wall cells
EP05022081A Withdrawn EP1650312A3 (en) 2000-03-31 2001-03-29 Functional assay of high-density lipoprotein

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP01923023A Expired - Lifetime EP1272666B1 (en) 2000-03-31 2001-03-29 A functional assay of high-density lipoprotein

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP05022081A Withdrawn EP1650312A3 (en) 2000-03-31 2001-03-29 Functional assay of high-density lipoprotein

Country Status (9)

Country Link
EP (3) EP1272666B1 (en)
JP (2) JP4675539B2 (en)
AT (1) ATE306563T1 (en)
AU (3) AU4976201A (en)
CA (2) CA2404000C (en)
DE (1) DE60113976T2 (en)
DK (1) DK1272666T3 (en)
ES (1) ES2250378T3 (en)
WO (2) WO2001075168A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
GB0421176D0 (en) * 2004-09-23 2004-10-27 Poston Robin Treatment of atherosclerosis
ATE469174T1 (en) 2004-10-15 2010-06-15 Us Gov Health & Human Serv AMPHIPATHIC HELIX-SHAPED MULTIDOMAIN PEPTIDES AND METHOD FOR USE THEREOF
WO2007012100A1 (en) * 2005-07-27 2007-02-01 Technische Universität Graz Oxidised phospholipids comprising a fluorophore moiety and use in the determination of the presence of enzymes having antiatherogenetic activity
CA2659655A1 (en) 2006-08-08 2008-02-21 Alan M. Fogelman Salicylanilides enhance oral delivery of therapeutic peptides
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
WO2009032693A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
KR20110095288A (en) 2008-11-06 2011-08-24 바스큘라 바이오제닉스 리미티드 Oxidized lipid compounds and uses thereof
EP3189069B1 (en) 2014-07-31 2024-10-23 UAB Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
CA2968790A1 (en) 2014-11-26 2016-06-02 Vascular Biogenics Ltd. Oxidized lipids and treatment or prevention of fibrosis
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
WO2018063796A1 (en) 2016-09-28 2018-04-05 The Regents Of The University Of California Ezetimibe-associated apoa-1 mimetic peptides showing enhanced synergism
JP7084590B2 (en) * 2016-10-31 2022-06-15 国立大学法人大阪大学 Selection method and selection reagent for subjects in need of treatment for dyslipidemia
WO2018165574A1 (en) * 2017-03-10 2018-09-13 The Regents Of The University Of California Method for diagnosing risk for inflammatory disease through glycan profiling
CN115151815A (en) * 2020-02-25 2022-10-04 美迪恩斯生命科技株式会社 Method for analyzing nucleic acid drug and the like

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020897A1 (en) * 1996-11-15 1998-05-22 President And Fellows Of Harvard College Modulation of map kinase phosphatase 1 (mkp-1)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5820932Y2 (en) * 1979-01-27 1983-05-02 財団法人杉山産業化学研究所 TBA test strip for lipid peroxide measurement
JPS56117798A (en) * 1980-02-21 1981-09-16 Toyo Jozo Co Ltd Kit for measuring lipoid peroxide
JPS60133368A (en) * 1983-12-19 1985-07-16 Dai Ichi Pure Chem Co Ltd Immunological measurement
JPH01231897A (en) * 1988-03-11 1989-09-18 Fuji Photo Film Co Ltd Dry glucose-analyzing element
US5135716A (en) * 1989-07-12 1992-08-04 Kingston Diagnostics, L.P. Direct measurement of HDL cholesterol via dry chemistry strips
WO1994023302A1 (en) * 1993-04-07 1994-10-13 The Australian National University Immunological assay of oxidatively modified human low density lipoproteins in plasma
RU94044169A (en) * 1994-12-16 1996-10-20 И.А. Кочетов Multiple analytical member
US5958714A (en) * 1996-10-02 1999-09-28 Safety Associates, Inc. Test kits for determining at least two specific analytes in foods and other complex matrices
JP3428853B2 (en) * 1997-04-02 2003-07-22 東北電子産業株式会社 Method and apparatus for measuring the antioxidant power of a liquid sample
ATE385575T1 (en) * 1997-06-20 2008-02-15 Leuven Res & Dev EXPERIMENTAL SETUP, ANTIBODIES AND STANDARDS FOR THE DETECTION OF OXIDIZED AND MDA-MODIFIED LOW DENSITY LIPOPROTEINS
US5989803A (en) * 1997-09-05 1999-11-23 The Trustees Of Columbia University In The City Of New York Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020897A1 (en) * 1996-11-15 1998-05-22 President And Fellows Of Harvard College Modulation of map kinase phosphatase 1 (mkp-1)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DUFF JENNIFER L ET AL: "Mitogen-activated protein (MAP) kinase is regulated by the MAP kinase phosphatase (MKP-1) in vascular smooth muscle cells: Effect of actinomycin D and antisense oligonucleotides", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 13, 1995, pages 7161 - 7166, XP002325494, ISSN: 0021-9258 *
HUANG Y ET AL: "Oxidized LDL-containing immune complexes induce Fc gamma receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages.", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY. JUL 1999, vol. 19, no. 7, July 1999 (1999-07-01), pages 1600 - 1607, XP002325496, ISSN: 1079-5642 *
LAI K ET AL: "MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASE-1 IN RAT ARTERIAL SMOOTH MUSCLE CELL PROLIFERATION", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 98, no. 7, October 1996 (1996-10-01), pages 1560 - 1567, XP002058893, ISSN: 0021-9738 *
METZLER B ET AL: "Induction of mitogen-activated protein kinase phosphatase-1 by arachidonic acid in vascular smooth muscle cells.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 11 DEC 1998, vol. 273, no. 50, 11 December 1998 (1998-12-11), pages 33320 - 33326, XP002325495, ISSN: 0021-9258 *
REDDY SRINIVASA ET AL: "Mitogen-activated protein kinase phosphatase 1 activity is necessary for oxidized phospholipids to induce monocyte chemotactic activity in human aortic endothelial cells", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 20, 18 May 2001 (2001-05-18), pages 17030 - 17035, XP002325497, ISSN: 0021-9258 *
SUBBANAGOUNDER ET AL.: "EVIDENCE THAT PHOSPHOLIPID OXIDATION PRODUCTS AND/OR PLATELET-ACTIVATING FACTOR PLAY AN IMPORTANT ROLE IN EARLY ATHEROGENESIS IN VITRO AND IN VIVO INHIBITION BY WEB 2086", CIRCULATION RESEARCH, GRUNE AND STRATTON, BALTIMORE, US, no. 85, 20 August 1999 (1999-08-20), pages 311 - 318, XP002951988, ISSN: 0009-7330 *

Also Published As

Publication number Publication date
JP2003529775A (en) 2003-10-07
JP2003529375A (en) 2003-10-07
EP1272666B1 (en) 2005-10-12
EP1272666A1 (en) 2003-01-08
ATE306563T1 (en) 2005-10-15
JP4675539B2 (en) 2011-04-27
AU4976201A (en) 2001-10-15
ES2250378T3 (en) 2006-04-16
CA2404000A1 (en) 2001-10-11
AU4976101A (en) 2001-10-15
DK1272666T3 (en) 2006-02-27
CA2404350A1 (en) 2001-10-11
WO2001075168A1 (en) 2001-10-11
DE60113976T2 (en) 2006-07-27
EP1650312A3 (en) 2006-05-17
DE60113976D1 (en) 2006-02-23
EP1650312A2 (en) 2006-04-26
EP1274862A1 (en) 2003-01-15
CA2404000C (en) 2010-07-27
EP1272666A4 (en) 2004-09-22
WO2001075170A1 (en) 2001-10-11
AU2001249762B2 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
AU4976101A (en) Control of a gene induced by oxidized lipids in human artery wall cells
CN101078719B (en) Method for operating measuring meter and measuring meter
Vaughan et al. Oxidative stress reproduces placental abnormalities of preeclampsia
AU2085295A (en) Method for quantitatively determining cholesterol
DK0659275T3 (en) Analytical test apparatus with built-in negative and positive control
NO176293C (en) Method for determining a ligand in a sample using an optical waveguide and a device for carrying out the method
EP0348211A3 (en) Visual discrimination qualitative enzyme assay
DE69808071D1 (en) PROOF TEST USING MAGNETIC PARTICLES
SE9802402D0 (en) Method of diagnosing cardiovascular disease and early atherosclerosis
EP1424558A4 (en) Reagent for assaying laminin 5 antigen in biological sample and assay method
DE59812075D1 (en) Use of annexins as a lupus anticoagulant control or standard in coagulation tests
MX9604417A (en) Detection of analytes.
WO1998059068A1 (en) Method for assaying biological specimens for substances contained in the components thereof and reagent to be used in this method
DE69331585D1 (en) MONOCLONAL ANTIBODY SPECIFIC FOR THE FK-506-BINDING PROTEIN, METHOD FOR DETERMINING THE CONTENT OF FK-506-BINDING PROTEIN IN A SAMPLE AND REAGENT SET THEREFOR
DE50007096D1 (en) KIT AND METHOD FOR DETERMINING THE REDOX STATUS IN THE URINE
GB2237108A (en) Assay for enzyme activity
AU3571901A (en) Electrochemical method for detecting nucleic acids
DK0790494T3 (en) Multilayer test agent
Glick The future of clinical microchemical analysis.
JPS5564800A (en) Method and reagent for determination of acyl coenzyme a
Näslund et al. Release of small amounts of free fatty acids from human adipocytes as determined by chemiluminescence.
Feltus et al. Detection of biotin in individual sea urchin oocytes using a bioluminescence binding assay
AU557883B2 (en) Specimen slide for occult blood testing and test kit for occult blood in gastric fluid
Singh et al. Construction of a Micropycnometer for Determination of Density and Specific Gravity of Liquids and Solutions
Donaghy Autonomous Mathematical Models: Constructing Theories of Metabolic Control

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021001

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050506

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090328

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1052373

Country of ref document: HK